TENAX THERAPEUTICS, INC.
Income Statement
| Line Item | Mar 2026 | Mar 2025 | Apr 2015 | Jan 2015 | Oct 2014 | Jul 2014 | Apr 2014 | Jan 2014 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $49.3K | $0 | $0 | $0 | $-104.4K | $41.9K |
| Cost of Revenue | — | — | $0 | $0 | $0 | $0 | $98.5K | $410 |
| Gross Profit | — | — | $0 | $0 | $0 | $0 | $-133.5K | $180 |
| Gross Margin | — | — | 0.0% | — | — | — | 127.8% | 0.4% |
| Operating Expenses | ||||||||
| Research & Development | $11.5M | $5.7M | — | $1.2M | $2.6M | $966.5K | $785.6K | $689.7K |
| SG&A Expense | $5.0M | $5.7M | — | $1.9M | $1.6M | $1.4M | $9.6M | $1.8M |
| Operating Income | $-16.6M | $-11.3M | — | $-3.1M | $-4.1M | $-2.4M | $-10.5M | $-2.4M |
| Operating Margin | — | — | — | — | — | — | 10,029.6% | -5,807.8% |
| Interest Expense | — | $0 | — | $968 | $59 | $46.3K | $69.7K | $70.0K |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-15.7M | $-10.4M | — | $-2.9M | $-4.1M | $-2.2M | $-10.4M | $-3.4M |
| Net Margin | — | — | — | — | — | — | 9,970.6% | -8,004.3% |
| EPS (Basic) | $-0.35 | $-0.09 | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| EPS (Diluted) | $-0.35 | $-0.09 | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares Outstanding (Basic) | 45.2M | 109.8M | 5.14B | 15.44B | 15.43B | 15.19B | 5.14B | 28.16B |
| Shares Outstanding (Diluted) | 45.2M | 109.8M | 5.14B | 15.44B | 15.43B | 15.19B | 5.14B | 28.18B |
| Dividends Per Share | — | — | — | — | — | — | — | — |